Physician profile
Julia Briggs
NPI 1962168591
$15,649.40
in general payments reported to CMS, 2019-2025
36 companies · $9,593 in 2025
The $9,593 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $446 · 2023: $840 · 2024: $4,771 · 2025: $9,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,859 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,309 · Travel and Lodging: $871 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,859.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,308.86 |
| Travel and Lodging | $871.14 |
| Education | $164.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,271.59 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,677.71 | 2022-2025 | |
| Qol Medical, LLC | $953.72 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $870.20 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $710.37 | 2023-2025 | Epclusa, Livdelzi |
| Genzyme Corporation | $541.57 | 2024-2025 | |
| Pfizer INC. | $456.02 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $297.02 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $293.18 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $182.78 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $176.72 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals Lp | $158.53 | 2022-2023 | Farxiga |
| Intra-Sana Laboratories | $155.73 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Regeneron Pharmaceuticals, INC. | $144.95 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $138.10 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $132.92 | 2024 | Voquezna |
| Boston Scientific Corporation | $130.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $123.06 | 2024-2025 | Tremfya |
| Acadia Pharmaceuticals INC | $123.06 | 2024 | Nuplazid |
| Ipsen Biopharmaceuticals, INC | $109.60 | 2024-2025 | Iqirvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.94 | 2022-2024 | Lifevest |
| Organon LLC | $86.36 | 2023-2025 | Hadlima, Renflexis |
| Celltrion USA INC. | $83.81 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.86 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $79.53 | 2022-2023 | Xarelto |
| Melinta Therapeutics, LLC | $79.26 | 2022-2023 | Vabomere, Kimyrsa |
| Mallinckrodt Hospital Products INC. | $78.62 | 2024-2025 | Terlivaz |
| Aimmune Therapeutics, INC. | $76.37 | 2024-2025 | Zenpep |
| Celgene Corporation | $71.11 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $55.44 | 2024-2025 | Resmetirom, Rezdiffra |
| Kestra Medical Technology Services, INC. | $47.37 | 2023 | Assure Wcd |
| Evoke Pharma, INC. | $43.27 | 2023-2025 | Gimoti |
| Merck Sharp & Dohme LLC | $41.45 | 2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $38.53 | 2022-2023 | Camzyos, Eliquis |
| Nestle Healthcare Nutrition INC. | $24.72 | 2023 | |
| Braintree Laboratories, INC. | $20.93 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.